Hubbry Logo
CureVacCureVacMain
Open search
CureVac
Community hub
CureVac
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
CureVac
CureVac
CureVac
View on Wikipedia
from Wikipedia

Headquarters of CureVac in Tübingen

Key Information

CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA (mRNA). Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac has had approximately 375 employees since May 2018.[2]

At the beginning of the COVID-19 pandemic, CureVac was an early starter in the race to develop a German vaccine for protection against COVID-19, a disease caused by infection with the SARS-CoV-2 virus.[3] Clinical trials for the CureVac COVID-19 Vaccine (CVnCoV) began in June 2020, and in the same month, the German Federal Government invested €300 million in CureVac, with one of the terms of the agreement being that KfW will hold a stake of approximately 23% in the company.[3][4][5] In June 2021 the company announced that CVnCoV displayed inadequate results in Phase III clinical trials with only 47% efficacy.[6] In October 2021, the company announced it would be abandon further research and development into CVnCoV and would instead focus its efforts in collaborating with GSK to develop improved mRNA vaccine technology.[7][8]

The company's focus is on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. CureVac has entered into various collaborations with organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, Genmab, the Bill & Melinda Gates Foundation, Eli Lilly and Company, GlaxoSmithKline,[9][10] Coalition for Epidemic Preparedness Innovations, the International AIDS Vaccine Initiative,[11] and the government of Germany.[12]

History

[edit]

Research collaborations

[edit]

In 2007, Curevac received the innovation prize of the state of Baden-Württemberg[13] and was also the winner of the nationwide Weconomy competition, which is jointly awarded by the Handelsblatt newspaper and the Wissensfabrik.[14]

In October 2013, CureVac launched a collaboration with Janssen Pharmaceuticals Inc., a Johnson & Johnson company, for the development of novel flu vaccines.[15] Also in 2013, CureVac announced the fourth in a series of partnerships with the Cancer Research Institute and Ludwig Cancer Research to enable clinical testing of novel cancer immunotherapy treatment options.[16]

In March 2014, CureVac won a €2 million prize awarded by the European Commission to stimulate new vaccine technologies.[17] Later, in July 2014, CureVac signed an exclusive license agreement with Sanofi Pasteur to develop and commercialize an mRNA-based prophylactic vaccine.[18] By September 2014, the company licensed the global rights for its Phase I candidate – CV9202 – to Boehringer Ingelheim. Boehringer was to conduct trials using the mRNA vaccine in combination with afatinib in advanced and/or metastatic epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) as well as inoperable stage III NSCLC.[19]

In March 2015, a CureVac investor, the Bill & Melinda Gates Foundation, agreed to provide separate funding for several projects to develop prophylactic vaccines based on CureVac's proprietary mRNA platform.[20] By September 2015, CureVac entered into a collaboration with the International AIDS Vaccine Initiative (IAVI) to accelerate the development of AIDS vaccines, utilizing immunogens developed by IAVI and partners, delivered via CureVac's mRNA technology.[21] That same month, CureVac announced it would open a United States hub in Boston, Massachusetts.[22]

In accordance with its deal with Eli Lilly and Company, the company began construction on a production facility in 2016.[23]

In February 2019, the Coalition for Epidemic Preparedness Innovations (CEPI) awarded CureVac a $34 million grant to develop its proprietary "RNA printer" prototype.[24] The technology is expected to allow the company to rapidly produce mRNA vaccine candidates at scale from multiple locations globally to bypass the logistical hurdles that often delay the production of vaccines in response to infectious disease emergencies. It is also expected to enable the production of personalized medicines.[24] The initial uses would be for their candidate vaccines for Lassa fever, yellow fever, and rabies.[24]

In July 2020, Tesla, Inc CEO Elon Musk announced via a Tweet that Tesla and CureVac had reached an agreement to produce portable "RNA microfactories" based on this technology to manufacture CureVac's COVID-19 vaccine candidate.[24] CureVac had stated that the bioprinters would be able to produce “more than a hundred thousand doses” within approximately two weeks.[24] At approximately the same time, Tesla and CureVac filed a joint patent on the technology.[25] In August, Musk reviewed the project with Curevac while in Germany.[25]

Investment

[edit]

By 2017, CureVac had received investments of approximately €305 million in the form of equity and was valued at €1.40 billion.[26] In June 2020, the federal government announced that the state-owned development bank KfW would immediately invest €300 million in CureVac, which will mean that it will hold a 23% stake in CureVac.[12]

On 14 August 2020, CureVac began public trading on the NASDAQ exchange under the ticker symbol, CVAC, raising $213 million in its initial public offering.[27]

Reports of Trump administration overtures

[edit]

On 11 March 2020, it was reported that CureVac AG's CEO Daniel Menichella was no longer the company's CEO, having been replaced by the company founder Ingmar Hoerr. Menichella was reported to have met U.S. President Donald Trump on 2 March.[28][29] According to Welt am Sonntag, quoting an anonymous German government source, Trump had attempted to persuade CureVac to relocate to the United States, a proposal vigorously rejected by German officials.[30] On 16 March, CureVac issued a statement on Twitter, stating "To make it clear again on coronavirus: CureVac has not received from the US government or related entities an offer before, during and since the Task Force meeting in the White House on March 2. CureVac rejects all allegations from press."[31]

Acquisition

[edit]

In June 2025, BioNTech announced its intention to buy CureVac in an all-stock deal valued at US$1.25 billion.[32]

COVID-19 vaccine candidate

[edit]
Main article: CureVac COVID-19 vaccine

CVnCoV is an mRNA vaccine that encodes a minimal piece of the coronavirus spike protein and activates the immune system against it.[33][34] CVnCoV technology does not interact with the human genome.[33]

In December 2020, CureVac began a Phase III clinical trial of CVnCoV with 36,500 participants.[35][36] Bayer will provide clinical trial support and international logistics for the Phase III trial and may be involved in eventual manufacturing should the vaccine prove to be safe and effective.[37] In January 2021, CureVac announced a clinical development collaboration for its COVID-19 vaccine, named CVnCoV (active ingredient zorecimeran), with the multinational pharmaceutical company Bayer.[37] As of December 2020, CVnCoV was in a Phase III clinical trial of 36,500 participants.[35][36] On 12 February 2021, CureVac announced the initiation of a rolling submission with the European Medicines Agency (EMA) for their vaccine candidate, a time-optimized process for the review of all data necessary for potential market authorization.[38] On 16 June 2021, the CureVac announced that Phase III trials of its mRNA vaccine showed an efficacy of 47%.[39] This falls short of the European Medicines Agency's target efficacy of at least 50%.[40]

Beyond CVnCoV, CureVac has also partnered with GlaxoSmithKline (GSK) to develop a new generation of mRNA-based COVID-19 vaccines. Human testing is due in late 2021.[41][needs update]

The start of the phase 1 study with the product candidate CV2CoV, which was announced for the fourth quarter of 2021, had to be postponed to the first quarter of 2022. Since an approval-relevant study for the new vaccine can only be carried out in the fourth quarter of 2022, the goal originally set for mid-October of “obtaining official approval for the marketability of an improved Covid-19 vaccine in 2022” can be achieved in 2023 at the earliest.[42][needs update]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

CureVac

View on Grokipedia
from Grokipedia
CureVac N.V. is a clinical-stage biopharmaceutical company headquartered in Tübingen, Germany, specializing in the development of messenger RNA (mRNA)-based therapeutics for vaccines against infectious diseases, cancer immunotherapies, and treatments for rare diseases. Founded in 2000 by Ingmar Hoerr, a biologist who pioneered early research into mRNA's potential for medical applications, the company positioned itself as the first to successfully apply mRNA technology toward therapeutic ends, filing initial patents on its use for vaccination and protein expression. CureVac's prominence surged during the with its first-generation, unmodified candidate CVnCoV, developed in collaboration with partners including the . In a phase 2b/3 randomized, observer-blinded (HERALD) involving over 11,000 participants across multiple countries, CVnCoV demonstrated 48% efficacy against symptomatic in the primary analysis for adults aged 18-60, with lower protection observed in older age groups and amid circulating variants like Beta and Gamma; this result, attributed in part to the vaccine's sequence targeting the original strain and lack of chemical modifications to the mRNA, led to the program's discontinuation in favor of next-generation efforts. 02400-5/fulltext) The trial's outcomes, published in peer-reviewed literature, highlighted challenges in design under evolving viral pressures, contrasting with higher efficacies reported for modified mRNA platforms. As of October 2025, CureVac continues to advance its mRNA pipeline, including and infectious disease programs, while undergoing a strategic acquisition by SE, announced in June 2025 via a definitive purchase agreement and public exchange offer for all outstanding shares, aimed at consolidating mRNA expertise and resources amid ongoing clinical and financial restructuring. The transaction, pending shareholder approval at a November 25, 2025, , reflects CureVac's evolution from independent innovator to integrated player in the mRNA field, following years of investment in proprietary platforms like RNActive® for stabilized mRNA delivery.

Overview

Company Profile and Founding

CureVac is a company headquartered in , , specializing in (mRNA) technology for medical applications. Founded in 2000 by biologist Ingmar Hoerr along with colleagues Steve Pascolo, Florian von der Mulbe, and Günther Jung, it holds the distinction as the world's first enterprise dedicated exclusively to developing mRNA-based therapeutics. Hoerr, who earned his doctorate in the late 1990s, drove the company's inception through his pioneering work on RNA's potential for inducing cellular protein expression without viral vectors, a concept that challenged prevailing paradigms reliant on DNA or viruses. The initial scope centered on harnessing synthetic mRNA to treat diseases by directing cells to produce therapeutic proteins, an approach that anticipated mRNA's broader utility long before its mainstream validation. Originally operating as a private entity focused on research and early-stage development, CureVac transitioned to public status with its on the Nasdaq Global Market on August 14, 2020, trading under the ticker symbol . This listing provided capital for scaling its mRNA platform while retaining its foundational commitment to non-viral nucleic acid innovations originating from Hoerr's foundational patents on mRNA stabilization and delivery.

Core Mission and mRNA Focus

CureVac's core mission is to harness (mRNA) as a data carrier to instruct human cells to produce therapeutic proteins, enabling the development of prophylactic vaccines and treatments for cancer and rare diseases. By optimizing mRNA sequences for enhanced stability and efficient translation, the company prioritizes applications that leverage the body's own machinery for targeted protein expression, such as antibody production or immune activation against pathogens and tumors. This approach focuses on empirical validation of mRNA's potential to address unmet medical needs through scalable, non-viral delivery systems. The company's pioneering efforts established mRNA's viability for medical use via early preclinical demonstrations of protein replacement and immune modulation. Founded in 2000 after foundational work on mRNA's intrinsic , CureVac achieved successes in inducing sustained protein expression in animal models and modulating immune responses through sequence-optimized constructs, overcoming initial challenges like rapid degradation and innate immune overactivation. These validations confirmed mRNA's capacity for direct tissue administration without prior reliance on cell manipulation. CureVac's mRNA platform underscores stability via proprietary (UTR) designs and codon optimization, coupled with early delivery using complexation to shield unmodified from nucleases while preserving its adjuvant-like . This method facilitated scalable manufacturing processes amenable to large-batch production and contrasted with viral vectors by enabling transient, non-integrating expression that minimizes risks of or pre-existing immunity. Such innovations positioned mRNA as a versatile alternative for both and therapeutic modalities.

Historical Development

Early Research and Milestones (2000-2015)

CureVac was established in 2000 in , , by Ingmar Hoerr, building on his Ph.D. discovery that naked (mRNA) could transfect cells to produce transient protein expression without genomic integration or the risks associated with viral vectors or DNA plasmids. Early experiments from 2000 to 2005 demonstrated that unmodified mRNA injected directly could elicit in animal models, highlighting its potential for therapeutic applications like and protein replacement while avoiding persistent genetic modification. From 2005 to 2010, CureVac advanced mRNA stabilization through sequence optimization techniques, focusing on non-coding regions such as 5' and 3' untranslated regions (UTRs) to enhance translation efficiency, prolong , and minimize activation of innate immune sensors like Toll-like receptors (TLRs) and RIG-I, which otherwise trigger rapid degradation and inflammation. These modifications enabled the use of non-chemically altered mRNA, preserving its natural structure while improving and reducing off-target immune responses, as validated in preclinical models of protein expression and . This foundational work culminated in the initiation of the first-in-human phase 1 trial (NCT02241135) of a prophylactic mRNA (CV7201) in October 2013, involving 101 healthy adults who received up to three doses of naked, sequence-optimized mRNA encoding the rabies virus to induce immune responses, administered intradermally or intramuscularly.31665-3/fulltext) The trial, completed by 2016, confirmed safety across doses from 80 to 640 μg and demonstrated robust — neutralizing titers exceeding protective thresholds in all participants at the lowest 1 μg dose after two immunizations—establishing proof-of-concept for mRNA vaccines in humans. By 2015, CureVac had operationalized GMP-compliant manufacturing facilities in , capable of producing clinical-grade mRNA under pharmaceutical standards, which facilitated the launch of phase 1 studies for personalized cancer immunotherapies using tumor-specific antigen-encoded mRNA to stimulate dendritic cells or direct T-cell responses. These facilities ensured scalability and quality control for individualized mRNA constructs derived from patient tumor sequencing, marking a shift from preclinical proof to testing of neoantigen-targeted vaccines.

Investments, Partnerships, and Expansion (2015-2019)

In March 2015, the Bill & Melinda Gates Foundation invested $52 million in equity in CureVac to advance its mRNA-based vaccine platform, particularly for applications in priorities such as maternal and child immunization. This funding, one of the foundation's largest single biotech commitments at the time, complemented an ongoing collaboration to develop low-cost, stable mRNA vaccines suitable for low-resource settings, emphasizing unmodified mRNA to enable thermostable formulations without cold-chain requirements. Dietmar Hopp, co-founder of and principal investor through dievini Hopp BioTech, maintained substantial equity stakes during this period, providing continuity as CureVac's lead backer and enabling sustained R&D scaling amid growing interest in mRNA therapeutics. By late 2015, CureVac secured an additional funding round totaling approximately $110 million, directed toward expanding its pipeline in and infectious diseases. To support international growth and access U.S. regulatory and clinical expertise, CureVac established a in , in September 2015, appointing Karen Slobod, M.D., as managing director; this move facilitated preclinical advancements, including promising data on mRNA rabies vaccine CV7201, which demonstrated robust neutralizing responses in animal models at low doses. By 2019, preclinical evaluations of mRNA candidates for further validated the platform's versatility, showing protective efficacy against viral challenges in and non-human primates, which bolstered preparations for broader clinical translation and potential IPO activities.

COVID-19 Era Challenges and Government Involvement (2020-2021)

In early 2020, amid the escalating , CureVac rapidly adapted its established mRNA platform—originally developed for infectious diseases and —to encode the spike protein, initiating preclinical studies for a by March. This pivot leveraged the company's prior expertise in unmodified mRNA technology, enabling swift progression to clinical development under global urgency. To fund accelerated efforts, CureVac completed an on the on August 14, 2020, raising $213.3 million through the sale of 13.3 million shares priced at $16 each, with proceeds earmarked primarily for its COVID-19 program and manufacturing expansion. International tensions emerged in March 2020 when reports surfaced of overtures from the Trump administration to secure exclusive U.S. access to CureVac's technology, including an alleged $1 billion offer to relocate operations or negotiate rights solely for American use. The German government swiftly intervened, affirming CureVac as a "national asset" and imposing export controls to prevent technology transfer, with Economy Minister stating such a deal would not be permitted. CureVac's CEO Ingmar Hoerr confirmed discussions occurred but denied any exclusive agreement, emphasizing commitment to broader access. This episode highlighted geopolitical frictions over , prompting the to offer up to €80 million in immediate support to retain development in . German federal authorities provided substantial backing, investing €300 million in June 2020 to bolster CureVac's capacity as a key domestic player in mRNA innovation. In September 2020, the government allocated up to €252 million from the Federal Ministry of Education and Research—part of a €445 million package shared with —for vaccine advancement and production scaling, aiming to enhance amid surging . At the EU level, CureVac entered an advance purchase agreement in 2020 for potential supply of up to 225 million doses, contingent on regulatory approval, as part of the bloc's joint procurement strategy paralleling U.S. initiatives like . Despite this support, CureVac encountered scaling hurdles in 2020-2021, including delays in building a complex production network for commercial volumes, which lagged behind U.S. competitors like that benefited from earlier federal contracts and domestic advantages. These challenges stemmed from reliance on specialized mRNA and fill-finish processes, requiring new facilities and partnerships, even as German subsidies facilitated expansion in and beyond. By late 2020, efforts to ramp up yielded preclinical feasibility but highlighted bottlenecks in yield optimization and regulatory-aligned scaling compared to rivals' accelerated timelines.

mRNA Technology Platform

Unmodified mRNA Principles and Advantages

CureVac's mRNA platform employs unmodified messenger RNA (mRNA) composed of natural nucleosides, eschewing chemical modifications such as substitutions used by other developers. This approach leverages sequence engineering, including codon optimization to enhance translation efficiency and reduce recognition by receptors, alongside engineered 5' cap structures and untranslated regions (UTRs) to stabilize the molecule. Upon cellular uptake, the mRNA is translated into protein in the without entering the nucleus or altering the host genome—distinguishing it from gene therapy, which involves permanent DNA modification— with proprietary optimizations extending protein expression: peak levels occur 24 to 48 hours post-injection, persisting for several days in preclinical models. The retention of unmodified nucleosides preserves the mRNA's inherent immunostimulatory properties, which activate innate immune pathways like Toll-like receptors and RIG-I, thereby promoting robust adaptive responses, particularly CD8+ T-cell activation essential for cellular immunity. In a phase 1 proof-of-concept trial for the rabies vaccine candidate CV7201 (NCT02241135) using 1 μg doses of unmodified mRNA, participants developed neutralizing titers comparable to those from licensed inactivated vaccines at 80 IU doses, alongside T-cell responses detected via interferon-γ assays. This immunogenicity at low doses underscores the platform's efficiency in eliciting multifaceted immunity without exogenous adjuvants. Sequence-optimized unmodified mRNA mitigates excessive innate activation—via reduced secondary structures and codon bias—while avoiding potential drawbacks of chemical modifications, such as altered fidelity or unforeseen long-term autoimmune risks from synthetic analogs. Preclinical comparisons indicate that such designs yield comparable protein expression to modified counterparts but with a more balanced profile, potentially lowering risks of aberrant immune activation. This framework supports applications requiring sustained and T-cell priming, as evidenced by prolonged transgene expression .

Limitations and Comparisons to Competitors' Approaches

Unmodified mRNA, as employed in CureVac's platform, elicits heightened activation of Toll-like receptors (TLRs), such as TLR7 and TLR8, through recognition of motifs, triggering innate immune pathways that promote production, RNase activation, and subsequent mRNA degradation, thereby limiting translation efficiency and expression. This intrinsic , while providing adjuvanticity, results in shorter mRNA persistence in preclinical models, with rapid clearance reducing the duration of compared to less inflammatory alternatives. In contrast, competitors like / and utilize pseudouridine-modified mRNA to suppress TLR signaling and evade RNase L-mediated decay, enhancing mRNA stability, cellular uptake, and translational output, which preclinical studies link to superior humoral immune responses through sustained . CureVac's sequence-optimized but chemically unmodified approach aims to retain "natural" innate sensing for broader immunity, yet animal data indicate it yields comparatively lower titers, prioritizing potential cytotoxic T-cell priming over peak humoral potency. Empirical trade-offs are evident in biodistribution and assays: unmodified mRNA demonstrates an edge in eliciting + T-cell responses via vigorous type I signaling, but this comes at the cost of diminished B-cell activation and antibody production in models, underscoring design choices that favor cellular over humoral arms despite overall reduced against requiring high neutralizing titers. These limitations highlight causal dependencies on innate sensing intensity, where excessive early curtails long-term availability without compensatory modifications.

COVID-19 Vaccine Candidate

Development of CVnCoV

CureVac initiated development of CVnCoV, its mRNA-based vaccine candidate, in early by selecting a sequence encoding the full-length viral , incorporating stabilizing substitutions at positions K986 and V987 to maintain a prefusion conformation conducive to eliciting neutralizing antibodies. The unmodified mRNA was optimized for high expression levels and balanced immune using CureVac's RNActive platform, with encapsulation in nanoparticles for delivery. To address logistical challenges, CVnCoV was formulated for , demonstrating stability for at least three months at 2–8°C (refrigerator conditions) and up to 24 hours at ambient temperatures around 25°C, thereby eliminating the need for ultra-cold storage chains required by some competing mRNA vaccines. Preclinical evaluations conducted in 2020 confirmed and protective . In Syrian hamsters, a single dose of CVnCoV induced high levels of neutralizing antibodies and provided full protection against challenge, preventing in lungs. Subsequent studies in non-human primates demonstrated robust humoral and cellular responses, with vaccinated animals showing efficient reduction in upon challenge infection. These results supported advancement to human trials, with phase 1 studies commencing in July 2020 to assess safety across dose levels. Interim phase 1 data from November 2020 indicated CVnCoV was generally well-tolerated, with dose-dependent induction of binding and neutralizing antibodies comparable to levels in convalescent serum, alongside early T-cell signals. Phase 2a/2b trials followed in late 2020, further characterizing reactogenicity and at the selected 12 μg dose, confirming a favorable profile and strong responses in hundreds of participants. Parallel efforts focused on manufacturing scale-up, leveraging German government funding of approximately €300 million and partnerships to expand capacity from initial pilot production to up to 300 million doses annually by mid-2021, primarily at facilities in . This ramp-up included process optimization for mRNA production and fill-finish operations to meet potential demand under advance purchase agreements.

Phase 3 Trials and Efficacy Data

The HERALD trial (NCT04652102) was a randomized, observer-blinded, -controlled phase 2b/3 study evaluating the and of CVnCoV, conducted across 47 centers in ten countries including , the , , , , the , , , , and the , with primary enrollment in and . Enrollment began in December 2020 and involved 39,680 participants aged 18 years and older, randomized 2:1 to receive two doses of 12 μg CVnCoV or 28 days apart. The primary endpoint was the prevention of symptomatic disease of any severity starting 14 days after the second dose, confirmed by RT-PCR and adjudication. An on June 16, 2021, after 134 adjudicated cases, reported an overall vaccine efficacy (VE) of 47% (95% CI not specified in interim release) against of any severity, based on sequenced cases showing 57% due to variants of concern (including Alpha and Gamma), 21% Lambda (C.37), and only 1% original Wuhan strain. Efficacy appeared higher in younger participants (under 60 years) but inconclusive in those aged 60 and older due to limited cases and variant diversity across 13 strains. The analysis did not meet prespecified statistical success criteria for the primary endpoint, attributed to the rapidly evolving viral landscape, though the Data Safety Monitoring Board confirmed a favorable safety profile. The final primary efficacy analysis, reported on June 30, 2021, after 228 adjudicated cases (83 in CVnCoV recipients vs. 145 in ), yielded an overall VE of 48.0% (95% CI: 31.0–61.4%; p=0.016) against symptomatic of any severity. Of 204 sequenced cases, 86% involved variants of concern or interest (predominantly Alpha at 92% in and Gamma in ), with efficacy estimates ranging 42–67% across 15 strains in the 18–60 age group. Against moderate-to-severe disease, VE was 70.7% overall (95% CI: 42.5–86.1%), with zero hospitalizations or deaths in vaccinated participants aged 18–60 versus six in recipients of the same age group.
Age GroupAny Severity VE (95% CI)Cases (Vaccine vs. Placebo)Moderate/Severe VE (95% CI)
18–60 years52.5% (36.2–64.8%)71 vs. 13677% (not specified)
≥61 yearsInsufficient cases for reliable estimateLimited (e.g., higher incidence in elderly placebo)Not reliably estimable
Severe disease cases were low overall (four in CVnCoV vs. ten in ), precluding calculable VE, though post-hoc subgroup data indicated no severe outcomes in younger vaccinated participants. The trial met prespecified case accrual thresholds for analysis but highlighted challenges from dominance, with only ~3% of cases from the original strain. No hazard ratios were reported; efficacy was derived from conditional adjusted for age and effects.

Withdrawal from Regulatory Review

On June 16, 2021, CureVac announced an interim analysis from its Phase 2b/3 HERALD trial of CVnCoV, revealing an of 47% against symptomatic , prompting internal reassessment and discussions with the (EMA) regarding the vaccine's path to . The full dataset, released on June 30, 2021, confirmed an overall of 48% (83 cases in the vaccine group versus 145 in ), with higher against severe but insufficient overall performance to meet standard thresholds amid rising variant pressures. The EMA's rolling review, initiated on February 12, 2021, continued through the summer, but evolving epidemiological factors—including the dominance of variants like Delta and a shift toward booster strategies for existing —diminished CVnCoV's viability. In early October 2021, following EMA feedback indicating the earliest possible approval would be in Q2 2022, CureVac withdrew its application on , citing the combination of modest efficacy data, prolonged timelines, and reduced need for first-generation candidates. The EMA formally ended the rolling on October 12, 2021. In the immediate aftermath, CureVac redirected manufacturing capacity and resources from CVnCoV production to its second-generation bivalent candidate, CV2CoV, which remained in at the time of withdrawal but advanced toward clinical in with GlaxoSmithKline. This pivot included reallocating commitments under prior advance purchase agreements and writing down inventory related to the abandoned first-generation vaccine, contributing to financial strains reported in subsequent quarterly updates.

Post-COVID Pipeline and Programs

Oncology and Cancer Therapies

CureVac's oncology efforts center on mRNA platforms designed to elicit targeted immune responses against solid tumors, particularly through individualized neoantigen vaccines and adjuvants that enhance innate immunity. Following challenges with its , the company pivoted to cancer applications, leveraging unmodified mRNA to encode tumor-specific antigens or mimic viral patterns for broad immune activation. These approaches aim to overcome tumor by stimulating both innate and adaptive responses, often in combination with existing therapies like checkpoint inhibitors. A key early program is CV8102, a non-coding mRNA acting as a Toll-like receptor 7/8 (TLR7/8) and retinoic acid-inducible gene I (RIG-I) agonist, intended for intratumoral injection to induce local and systemic antitumor immunity. In a phase 1 trial (NCT03291002) involving patients with advanced cutaneous , squamous cell carcinoma of the skin or head/neck, and , CV8102 monotherapy and combination with PD-1 inhibitors demonstrated a favorable safety profile, with grade 1-2 adverse events predominantly injection-site reactions and flu-like symptoms. Preliminary efficacy included tumor regression in injected and non-injected lesions, alongside induction of systemic immune responses such as increased signatures and T-cell activation, as reported in expansion cohorts evaluated through 2022 and updated in 2025 analyses. CureVac has advanced personalized neo-targeted mRNA vaccines, particularly for , through programs like CVGBM, which uses next-generation sequencing to identify patient-specific tumor mutations for customized encoding. In a phase 1 study of newly diagnosed patients post-resection and standard chemoradiotherapy, CVGBM induced robust, tumor-specific T-cell responses in the majority of treated individuals, with detectable neoantigen-reactive + and + T cells persisting months after , as presented at the ESMO in September 2024. Expansion to further cohorts is planned for late 2025 to assess potential progression to later phases, building on collaborations such as the 2024 co-development agreement with for novel mRNA cancer vaccines incorporating neoantigen discovery. Validating the platform's adaptability, the U.S. FDA granted (IND) clearance on April 7, 2025, for a phase 1 trial of CVHNLC, an off-the-shelf mRNA precision comprising two constructs encoding eight tumor-associated antigens tailored for squamous non-small cell (sqNSCLC). This open-label, dose-escalation study will evaluate safety and tolerability of CVHNLC combined with in advanced sqNSCLC patients, targeting shared neoantigens to prime adaptive immunity against immunosuppressive tumor microenvironments.

Other Infectious Disease and Therapeutic Efforts

CureVac has pursued mRNA-based vaccines for , with CV7201, an unmodified mRNA candidate, demonstrating safety and immunogenicity in phase 1 trials completed in 2017. Administered via needle-free , doses as low as 1 μg or 2 μg elicited neutralizing responses meeting pre-exposure prophylaxis criteria in all recipients after two doses, with seroconversion rates reaching up to 83% above the 0.5 IU/mL threshold.31665-3/abstract) The platform's potential for single-dose was supported by preclinical indicating robust protection, though trials emphasized low-dose tolerability over multi-dose regimens. In development, CureVac's collaboration with GSK has advanced seasonal candidates to phase 2, with interim data from April 2024 showing promising against A and B strains following a single administration. In phase 1 trials among older adults, the monovalent H1N1-encoding FLU-SV-mRNA achieved rates of 89.7%, surpassing the 56.2% rate of a licensed comparator , alongside elevated titers. Phase 2 results confirmed acceptable safety profiles and immune responses supporting progression to phase 3 in 2025, including multivalent formulations and a / combination initiated in November 2024. These efforts leverage CureVac's mRNA stabilization techniques to enhance global thermostability and access. Beyond vaccines, CureVac has explored mRNA therapeutics for rare diseases through protein replacement approaches, targeting enzyme deficiencies in preclinical models. This includes applications for conditions like , where mRNA encoding functional CFTR protein has demonstrated restorative potential and in animal studies, addressing underlying genetic defects via transient expression. As of late 2024, these programs remain in early discovery, with no clinical-stage IND filings reported for cystic fibrosis-specific therapies, focusing instead on platform optimization for durable protein production.

Controversies and Criticisms

Vaccine Efficacy Debates and Technical Shortcomings

CureVac attributed the low efficacy of CVnCoV in its phase 2b/3 HERALD trial—reporting 47% protection against symptomatic of any severity in an interim analysis on June 16, 2021—to extensive antigenic drift at trial sites in and , where variants including Gamma (P.1) and (C.37) comprised significant portions of sequenced cases, diverging substantially from the vaccine's Wuhan-Hu-1 spike antigen. Final analyses confirmed efficacy at 48% overall, with subgroup variations (e.g., 53% in adults aged 18-60), but emphasized that 15 distinct lineages circulated, reducing matched-strain protection and exposing the vaccine to polyclonal challenge environments. Critics, including analyses in peer-reviewed literature, countered that variant mismatch alone inadequately explained the shortfall, pointing instead to causal flaws in the unmodified mRNA design, which triggers robust innate immune activation via pattern recognition receptors like Toll-like receptors, thereby suppressing eukaryotic translation and yielding inferior expression relative to nucleoside-modified platforms (e.g., in Pfizer-BioNTech and vaccines). This inherent instability necessitated a low 12 μg dose to mitigate reactogenicity—versus 30 μg for or 100 μg for —correlating with comparatively subdued neutralizing antibody titers; phase 1/2 data showed CVnCoV inducing rates akin to competitors but with titers against pseudovirus roughly 40-60% lower post-dose 2. Such deficiencies manifested empirically as diminished protection against even ancestral strains in variant-prevalent settings, underscoring how unmodified mRNA's self-adjuvanting properties, while theoretically beneficial, compromised load in real-world deployment. Despite these shortcomings, proponents of unmodified mRNA hypothesized advantages in immune profiling, including amplified innate signaling that could promote Th1-skewed responses—evidenced by elevated IFN-α and IL-7 in preclinical models—potentially balancing Th1/Th2 cytokines to avert risks theorized for Th2-dominant vaccines, though no clinical ADE was observed with CVnCoV and such benefits remain unproven absent direct comparative T-cell data. The trial's outcomes illuminated fundamental mRNA trade-offs: unmodified sequences evade chemical risks but falter under translational interference, particularly amid variant polyclonality, where sustained high-avidity humoral and cellular responses demand maximal —a threshold unmet by CVnCoV's architecture.

Government Interventions and National Interest Claims

In March 2020, the Trump administration reportedly offered substantial financial incentives, estimated at up to $1 billion, to CureVac to relocate its coronavirus vaccine research operations to the or secure exclusive rights for American use, prompting immediate opposition from German officials who described the company as a "crown jewel" of national and vowed it was "not for sale." Although CureVac publicly denied receiving a formal takeover proposal or agreeing to any relocation, the episode heightened U.S.- tensions, with accelerating domestic support to retain control over the firm's mRNA platform and prevent its integration into U.S. initiatives like . To safeguard national interests, the German government invested €300 million in June 2020 for a 23% stake in CureVac, followed by up to €252 million in additional funding from the Federal Ministry of Education and Research in September 2020 for vaccine development and manufacturing expansion, supplemented by €75 million in loans from the European Commission and European Investment Bank. These interventions, totaling over €600 million in combined German and EU support, enabled clinical trials but were accompanied by regulatory frameworks in the European Union that imposed stricter bureaucratic requirements compared to the U.S. Food and Drug Administration's emergency use authorizations, which facilitated rapid scaling for competitors like Pfizer-BioNTech. Proponents of these measures, including German Economy Minister , argued they preserved strategic autonomy and protected vital for security amid global competition. Critics, however, contended that blocking U.S. capital inflows and Warp Speed collaboration limited access to vast resources—such as the billions in U.S. funding that propelled other mRNA vaccines—potentially misallocating CureVac's efforts through constrained funding and slower regulatory paths, thereby undermining broader innovation incentives in a high-stakes race. This approach prioritized sovereignty over market-driven efficiencies, contrasting with BioNTech's U.S. partnership model that accelerated global deployment.

Key Litigations with , , and GSK

In June 2022, CureVac initiated proceedings against in the Regional Court of , , alleging that 's Comirnaty infringed one European (EP 1 780 211) and three German utility models related to mRNA sequence optimization techniques, including adjustments to G/C content and codon usage for improved stability and reduced . CureVac sought injunctive relief to halt 's and activities in , asserting that Comirnaty's mRNA design overlapped with CureVac's proprietary methods for stabilizing synthetic mRNA through base-pairing enhancements and codon adaptations that minimize content while maximizing translational efficiency. The German suit highlighted evidence from Comirnaty's sequence data, where CureVac claimed direct parallels in the coding region's codon optimization and secondary structure stabilization, technologies CureVac developed over a prior for therapeutic mRNA applications. countered by challenging the validity of the asserted rights at the , but the court proceedings advanced with postponements on infringement rulings pending validity assessments. In May 2023, CureVac expanded its claims to the , filing a lawsuit in the Eastern District of against and , accusing them of infringing nine U.S. patents (later amended to include a tenth, such as U.S. No. 11,135,312) through the production, importation, and sale of Comirnaty. These patents covered foundational aspects of mRNA stabilization, including codon-optimized sequences with elevated G/C ratios to enhance protein expression and delivery efficiency via lipid nanoparticles. CureVac presented comparative analyses of trial data sequences, arguing that Comirnaty's design replicated patented features for mRNA longevity and immune evasion, originally pioneered for non-viral . Parallel to CureVac's actions, GSK pursued separate infringement claims against and starting in 2024, alleging violations of five GSK-held mRNA patents licensed in part from foundational technologies akin to CureVac's early collaborations, focusing on core mRNA formulation and delivery innovations tied to prior joint development efforts. These disputes stemmed from GSK's 2020 with CureVac on mRNA platforms, which involved licensing of stabilization and codon-related IP, though no direct adversarial litigation arose between CureVac and GSK. GSK sought remedies in multiple jurisdictions, including the , emphasizing overlapping foundational mRNA tech claims without invoking a specific 2018 fallout.

Resolutions and Settlements (2024-2025)

In August 2025, CureVac resolved its ongoing patent litigation with and over mRNA technology used in and vaccines, granting the companies a non-exclusive license to manufacture, use, import into the U.S., and sell such products. The agreement included aggregate payments of $740 million to CureVac and GlaxoSmithKline (GSK), along with single-digit royalties on future U.S. net sales of the relevant vaccines by and . As part of the resolution, GSK received a $370 million upfront payment from CureVac, supplemented by an additional $130 million in cash and 1% royalties on future non-U.S. sales of mRNA vaccines by and . This settlement encompassed all pending U.S. and European disputes, averting a scheduled U.S. that would have addressed infringement claims on CureVac's patents related to modified mRNA sequences and nanoparticles. The outcomes provided CureVac with immediate liquidity amid its reported cash outflows and enabled prioritization of pipeline commercialization over protracted legal risks, without conceding patent invalidity or non-infringement. GSK retained rights to enforce its separate patents against and outside this agreement. No similar resolutions occurred in 2024, with disputes intensifying prior to the 2025 breakthroughs.

Acquisition by BioNTech

Announcement and Strategic Rationale (2025)

On June 12, 2025, SE announced a definitive agreement to acquire all outstanding shares of CureVac N.V. through an all-stock public exchange offer, valuing CureVac at approximately $1.25 billion based on 's share price at the time. The transaction was positioned as a means to unite complementary mRNA platforms, leveraging CureVac's proprietary technologies alongside 's established capabilities in modified mRNA for enhanced development in and infectious disease therapies. BioNTech's strategic rationale emphasized gaining access to CureVac's unmodified mRNA , which differs from BioNTech's nucleoside-modified approaches and enables potential hybrid designs for improved therapeutic efficacy and stability. This integration was intended to accelerate advancements, particularly in cancer immunotherapies and next-generation , by combining CureVac's sequence-optimized platforms with BioNTech's clinical-stage assets and expertise. For CureVac, the deal addressed operational vulnerabilities following the underwhelming performance of its CVnCoV candidate, which reported 48% efficacy in phase 3 trials in 2021 and failed to secure regulatory approval, leading to persistent high cash burn rates of around €100 million per quarter in early 2025 amid limited revenue streams. The announcement came in the context of recent patent dispute resolutions, including an August 2025 settlement between CureVac and / over mRNA-related claims, which cleared legal hurdles and facilitated the merger's focus on synergistic R&D rather than litigation. This consolidation reflects broader industry trends toward mRNA platform integration amid maturing post-COVID markets, where standalone developers like CureVac struggled with scaling independent of large-scale production partners.

Deal Terms, Timeline, and Implications

The acquisition is structured as an all-stock transaction, with BioNTech offering approximately $5.46 in BioNTech American Depositary Shares (ADSs) for each outstanding CureVac share, implying an aggregate equity value of $1.25 billion based on the BioNTech ADS closing price on the announcement date. This fixed exchange ratio accounts for CureVac's approximately 229 million outstanding shares and is subject to customary adjustments for dividends, share issuances, or splits prior to closing. The timeline commenced with the definitive purchase agreement signed on June 12, 2025, followed by the launch of the public exchange offer on October 22, 2025. CureVac shareholders must register by October 28, 2025, to participate, with the offer period expiring at 9:00 a.m. ET on December 3, 2025, unless extended. Closing is anticipated after CureVac's (EGM) in November 2025 and upon receipt of regulatory clearances from authorities including the , U.S. antitrust bodies, and Germany's Federal Cartel Office, with no material adverse conditions. The deal's implications include enhanced synergies in mRNA platform development, particularly for oncology applications, by combining CureVac's lipid nanoparticle technologies and BioNTech's modular mRNA designs to accelerate candidates like individualized cancer vaccines. However, integration risks arise from overlapping research pipelines and CureVac's historical challenges, such as its COVID-19 vaccine's 48% efficacy in Phase 3 trials, potentially diluting focus amid broader mRNA technology skepticism post-pandemic. Long-term, the merger diversifies BioNTech's intellectual property portfolio, mitigating single-asset risks and supporting projected value creation through cost savings estimated at €100-200 million annually from shared manufacturing and R&D infrastructure, though actual shareholder returns hinge on clinical outcomes and market reception of combined assets.

References

  1. https://www.curevac.com/en/about-us/
  2. https://www.curevac.com/en/
  3. https://www.europabio.org/interview-with-ingmar-hoerr-curevac-founder-and-holder-of-the-first-patents-associated-with-mrna/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC8610426/
  5. https://www.nature.com/articles/s41587-022-01294-2
  6. https://www.curevac.com/en/curevac-initiates-strategic-restructuring-to-align-resources-with-focus-on-high-value-mrna-pipeline-opportunities/
  7. https://investors.biontech.de/news-releases/news-release-details/biontech-commences-public-exchange-offer-all-outstanding-shares
  8. https://www.tipranks.com/news/company-announcements/curevac-announces-extraordinary-meeting-for-merger-with-biontech
  9. https://www.insights.bio/vaccine-insights/journal/article/2570/RNA-pioneer-Ingmar-Hoerr-from-entrepreneur-to-philanthropist
  10. https://www.curevac.com/en/curevac-announces-pricing-of-initial-public-offering/
  11. https://synapse.patsnap.com/article/what-are-the-primary-areas-of-focus-for-curevac
  12. https://www.nature.com/articles/s41392-024-02002-z
  13. https://synapse.patsnap.com/article/what-is-the-research-and-development-focus-of-curevac
  14. https://www.curevac.com/en/technology/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC6368815/
  16. https://link.springer.com/article/10.1007/s00262-015-1746-9
  17. https://www.chemistryviews.org/details/ezine/11297010/Interview_with_Ingmar_Hoerr_Pioneer_of_mRNA_Technology/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC3991152/
  19. https://www.nature.com/articles/s41586-021-04231-6
  20. https://www.curevac.com/wp-content/uploads/2024/11/mRNA-sequence-parameters-and-formulation-optimization-increase-mRNA-therapeutics-performance.pdf
  21. https://pubmed.ncbi.nlm.nih.gov/28754494/
  22. https://www.tandfonline.com/doi/full/10.1586/14760584.2015.1000871
  23. https://www.curevac.com/en/curevac-announces-positive-results-in-low-dose-1-%25C2%25B5g-rabies-vaccine-clinical-phase-1-study/
  24. https://www.fiercepharma.com/deals/gates-foundation-puts-52m-behind-curevac-following-sanofi-boehringer-s-lead
  25. https://www.gatesfoundation.org/ideas/media-center/press-releases/2015/03/curevac-collaboration
  26. https://www.curevac.com/en/history/investment-by-dievini-hopp-biotech-von-dietmar-hopp/
  27. https://www.crunchbase.com/funding_round/curevac-series-f--7b2ec32c
  28. https://www.curevac.com/en/curevac-establishes-u-s-operations-in-cambridge-ma/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC6963972/
  30. https://drug-dev.com/curevacs-optimized-mrna-platform-provides-positive-preclinical-results-at-low-dose-for-covid-19-vaccine-candidate/
  31. https://www.cnbc.com/2020/08/14/coronavirus-vaccine-developer-curevac-raises-213-million-in-ipo.html
  32. https://www.reuters.com/article/business/coronavirus-vaccine-developer-curevac-raises-213-million-in-ipo-source-idUSKCN25A042/
  33. https://www.theguardian.com/world/2020/mar/16/not-for-sale-anger-in-germany-at-report-trump-seeking-exclusive-coronavirus-vaccine-deal
  34. https://www.politico.eu/article/germany-confirms-that-donald-trump-tried-to-buy-firm-working-on-coronavirus-vaccine/
  35. https://www.fiercebiotech.com/biotech/president-trump-tries-to-lure-curevac-to-make-a-u-s-vaccine-but-german-government-steps
  36. https://sciencebusiness.net/news/covid-19/eu-offers-eu80m-support-german-covid-19-vaccine-developer-reportedly-pursued-trump
  37. https://www.curevac.com/en/bundesregierung-beteiligt-sich-mit-300-millionen-euro-an-curevac/
  38. https://www.curevac.com/en/curevac-expected-to-receive-up-to-252-million-euros-from-the-german-federal-ministry-of-research-for-further-covid-19-vaccine-development-and-production-capacity-expansion/
  39. https://www.reuters.com/business/healthcare-pharmaceuticals/germany-grants-biontech-curevac-745-mln-speed-up-covid-19-vaccine-work-2020-09-15/
  40. https://commission.europa.eu/system/files/2021-01/curevac_-_redacted_advance_purchase_agreement_0.pdf
  41. https://www.piie.com/blogs/realtime-economics/2021/dont-let-curevacs-covid-19-vaccine-supply-chain-go-waste
  42. https://www.sciencedirect.com/science/article/pii/S0264410X23014779
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC7824029/
  44. https://www.nature.com/articles/s41573-021-00283-5
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC3597572/
  46. https://www.genomicseducation.hee.nhs.uk/blog/why-mrna-vaccines-arent-gene-therapies/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC7825876/
  48. https://www.curevac.com/en/curevac-announces-study-publication-in-molecular-therapy-demonstrating-wide-ranging-benefits-of-sequence-optimized-unmodified-mrnas/
  49. https://www.sciencedirect.com/science/article/pii/S216225312300121X
  50. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.983000/full
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC5475249/
  52. https://www.sciencedirect.com/science/article/pii/S1074761322005556
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC10280092/
  54. https://www.nature.com/articles/s41392-023-01579-1
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC5648897/
  56. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.789427/full
  57. https://www.sciencedirect.com/science/article/pii/S2162253125001428
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC11000609/
  59. https://link.springer.com/article/10.1007/s10238-023-01020-5
  60. https://www.citizen.org/wp-content/uploads/USG-Spike-Protein.pdf
  61. https://www.sciencedirect.com/science/article/pii/S1074761321003034
  62. https://www.nature.com/articles/s41541-021-00311-w
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC8052455/
  64. https://www.curevac.com/en/curevacs-covid-19-vaccine-candidate-cvncov-suitable-for-standard-fridge-temperature-logistics/
  65. https://link.springer.com/article/10.1208/s12249-021-01974-3
  66. https://www.curevac.com/wp-content/uploads/2020/10/20201023-CureVac-Manuscript-draft-preclinical-data.pdf
  67. https://www.biorxiv.org/content/10.1101/2020.12.23.424138.full
  68. https://www.curevac.com/en/curevacs-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-of-non-human-primates-during-sars-cov-2-challenge-infection/
  69. https://www.curevac.com/en/curevac-reports-positive-interim-phase-1-data-for-its-covid-19-vaccine-candidate-cvncov/
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC9247226/
  71. https://www.fiercepharma.com/manufacturing/curevac-scores-85m-loan-to-scale-covid-19-shot-manufacturing-at-german-site
  72. https://www.genengnews.com/news/curevac/
  73. https://www.curevac.com/wp-content/uploads/2020/11/20201130_PR_CureVac_Q3_9M-Results_EN_final.pdf
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC8447169/
  75. https://clinicaltrials.gov/study/NCT04652102
  76. https://www.curevac.com/en/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov/
  77. https://www.curevac.com/wp-content/uploads/2021/06/20210630_PR_CV_Final-analysis-of-Phase-2b-3-clinical-trial-for-CVnCoV_EN_Final.pdf
  78. https://www.curevac.com/wp-content/uploads/2021/06/20210616_PR-CV_Update-on-Phase-2b-3-Clinical-Trial-HERALD_Final.pdf
  79. https://www.curevac.com/en/curevac-final-data-from-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov-demonstrates-protection-in-age-group-of-18-to-60/
  80. https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-public-health-emergency-international-concern-2020-23/withdrawn-applications-products
  81. https://www.curevac.com/en/curevac-to-shift-focus-of-covid-19-vaccine-development-to-second-generation-mrna-technology/
  82. https://www.ema.europa.eu/en/news/ema-ends-rolling-review-cvncov-covid-19-vaccine-following-withdrawal-curevac-ag
  83. https://www.curevac.com/en/curevac-announces-financial-results-for-the-third-quarter-and-first-nine-months-of-2021-and-provides-business-update/
  84. https://www.curevac.com/wp-content/uploads/2024/09/20240910-CureVac-Investor-Handout.pdf
  85. https://pubmed.ncbi.nlm.nih.gov/39904560/
  86. https://www.curevac.com/en/curevac-presents-preliminary-data-from-phase-1-study-expansion-of-oncology-candidate-cv8102/
  87. https://www.curevac.com/en/curevacs-cvgbm-cancer-vaccine-induces-promising-immune-responses-in-phase-1-study-in-glioblastoma-presented-at-the-esmo-2024-congress/
  88. https://www.mdanderson.org/newsroom/md-anderson-curevac-enter-strategic-collaboration-develop-novel-cancer-vaccines.h00-159696756.html
  89. https://www.curevac.com/wp-content/uploads/2025/05/20250520-CureVac-Investor-Handout.pdf
  90. https://www.curevac.com/en/curevac-receives-u-s-fda-ind-clearance-to-initiate-phase-1-clinical-trial-for-novel-mrna-based-precision-immunotherapy-in-squamous-non-small-cell-lung-cancer/
  91. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1099991/full
  92. https://www.curevac.com/en/curevac-announces-publication-in-the-lancet-of-first-ever-human-proof-of-concept-study-investigating-the-safety-and-immunogenicity-of-a-prophylactic-mrna-vaccine/
  93. https://www.curevac.com/en/newsroom/news/
  94. https://www.curevac.com/en/curevac-partner-gsk-announces-positive-phase-2-data-from-seasonal-influenza-mrna-vaccine-program/
  95. https://www.curevac.com/en/curevac-announces-positive-data-in-older-adults-from-covid-19-and-flu-mrna-vaccine-development-programs/
  96. https://www.sec.gov/Archives/edgar/data/1809122/000141057825000692/cvac-20241231x20f.htm
  97. https://www.sciencedirect.com/science/article/pii/S1525001625002084
  98. https://www.curevac.com/wp-content/uploads/2021/07/20210107_CureVac_Final-Analysis-of-Pivotal-Phase-2b-3_Presentation_FINAL.pdf
  99. https://www.researchgate.net/publication/352741794_What_went_wrong_with_CureVac%27s_mRNA_vaccine
  100. https://pmc.ncbi.nlm.nih.gov/articles/PMC9535876/
  101. https://www.sciencedirect.com/science/article/abs/pii/S1473309921006770
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC8473088/
  103. https://pdfs.semanticscholar.org/d5dc/3a84a87b1a634ff3509d591afbac7f6d9bdd.pdf
  104. https://www.nytimes.com/2020/03/15/world/europe/cornonavirus-vaccine-us-germany.html
  105. https://www.reuters.com/article/business/healthcare-pharmaceuticals/german-biotech-curevac-says-it-has-had-no-us-takeover-offer-idUSL8N2BA4O9/
  106. https://www.cnbc.com/2020/03/15/coronavirus-germany-tries-to-stop-us-luring-away-firm-seeking-vaccine.html
  107. https://www.eib.org/en/press/all/2020-181-germany-eib-and-european-commission-provide-curevac-with-a-eur75-million-financing-for-vaccine-development-and-expansion-of-manufacturing
  108. https://www.bmj.com/content/368/bmj.m1100
  109. https://www.washingtonpost.com/world/europe/germany-coronavirus-curevac-vaccine-trump-rights/2020/03/15/8d684c68-6702-11ea-b199-3a9799c54512_story.html
  110. https://www.juve-patent.com/cases/curevac-files-vaccine-patent-infringement-claim-against-biontech-in-dusseldorf/
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC9669595/
  112. https://www.curevac.com/en/curevac-reports-progress-in-intellectual-property-infringement-case-against-biontech-in-germany/
  113. https://patents.google.com/patent/EP1604688A1/en
  114. https://www.curevac.com/en/curevac-announces-developments-in-patent-litigation-with-pfizer-biontech/
  115. https://www.marshallip.com/news/marshall-gerstein-counsels-curevac-through-global-resolution-of-patent-litigation-with-pfizer-biontech/
  116. https://patents.google.com/patent/WO2002098443A2/en
  117. https://www.bigmoleculewatch.com/wp-content/uploads/sites/2/2023/11/EDVA-2-23-cv-00222-56.pdf
  118. https://law.justia.com/cases/federal/district-courts/virginia/vaedce/2:2023cv00222/538042/368/
  119. https://www.lexology.com/library/detail.aspx?g=649b4c1a-92ab-4c84-81ab-bd655f9a50b1
  120. https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-to-restructure-collaboration-into-new-licensing-agreement/
  121. https://www.juve-patent.com/cases/mrna-patent-wars-kick-into-higher-gear-during-dog-days-of-summer/
  122. https://www.curevac.com/en/curevac-announces-resolution-of-patent-litigation-with-pfizer-biontech/
  123. https://investors.biontech.de/news-releases/news-release-details/biontech-reaches-agreement-receive-non-exclusive-license-mrna
  124. https://www.sec.gov/Archives/edgar/data/1809122/000110465925075352/tm2522930d1_ex99-1.htm
  125. https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-us-settlement-of-curevacbiontech-mrna-patent-litigation/
  126. https://www.gsk.com/media/p3dnhgc4/final-curevacbiontech-mrna-patent-litigation-080725.pdf
  127. https://www.curevac.com/en/curevac-announces-financial-results-for-the-second-quarter-and-first-half-of-2025-and-provides-business-updates/
  128. https://www.reuters.com/business/healthcare-pharmaceuticals/curevac-gsk-settle-mrna-patent-dispute-with-pfizer-biontech-2025-08-08/
  129. https://investors.biontech.de/news-releases/news-release-details/biontech-announces-strategic-transaction-acquire-curevac-public
  130. https://www.pharmaceuticalcommerce.com/view/biontech-launches-public-exchange-offer-for-curevac
  131. https://www.curevac.com/en/biontech-announces-strategic-transaction-to-acquire-curevac-in-public-exchange-offer/
  132. https://www.bigmoleculewatch.com/2025/06/27/biontech-announces-transaction-to-acquire-curevac/
  133. https://www.goodwinlaw.com/en/insights/blogs/2025/06/biontech-announces-transaction-to-acquire-curevac
Add your contribution
Related Hubs
User Avatar
No comments yet.